Clinical Trials Logo

Thoracic Cancer clinical trials

View clinical trials related to Thoracic Cancer.

Filter by:

NCT ID: NCT05053230 Recruiting - Ovarian Cancer Clinical Trials

A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer

IMPROVE
Start date: September 20, 2021
Phase: N/A
Study type: Interventional

The overarching long-term goal of the Integrative Medicine for Patient-reported Outcomes Values and Experience (IMPROVE) research program is to evaluate whether integrating a virtual mind-body programming, Integrative Medicine at Home (IM@Home), will improve patient perceived values, outcomes, and experiences as they undergo systemic cancer treatment such as chemotherapy, immunotherapy, radiotherapy, targeted agents, cytoreductive surgery.

NCT ID: NCT04837950 Recruiting - Thoracic Cancer Clinical Trials

Changes in Pleural Cavity Volume and Surgical Exposure

Start date: September 29, 2020
Phase: N/A
Study type: Interventional

The investigators want to investigate if a diaphragmatic traction-suture affects the pleural cavity volume, as well as improves visual overview of a surgical field during minimally invasive thoracic surgery.

NCT ID: NCT04799561 Recruiting - Thoracic Cancer Clinical Trials

Teleprehabilitation for Surgical Cancer Patients

Start date: March 12, 2021
Phase: N/A
Study type: Interventional

There is a general concern that the backlog of cancer patients waiting for surgery during this period is going to increase and the general impact on patients isolated in their homes is going to cause potential physiological and psychological impairments. Therefore, we propose a distanced-delivered personalized home-based prehabilitation program to all cancer patients scheduled for surgery at the MUHC. The program will be delivered by qualified professionals, supported by technology provided by POP, to all cancer patients waiting for surgery, addressing the patients' risk factors in patients' pandemic reality perspective. Participant contacts will primarily occur virtually using technologies such as video conferencing and digital applications. This will enable us to continue to support people with cancer and deliver safe remote counseling by specialist healthcare providers in their own homes, whilst adhering to the Governmental guidelines on social distancing, self-isolation and shielding.

NCT ID: NCT04776005 Recruiting - Solid Tumor Clinical Trials

COVID-19 Vaccine Efficacy in Patients With Malignant Pathologies

COVIDVAC OH
Start date: January 22, 2021
Phase:
Study type: Observational

In the context of malignant disease, it is likely that vaccine efficacy and immunogenicity depends on the type of pathology, stage of the disease, immunosuppression induced by the treatments, in addition to more classic factors such as age, general condition and possibly the type of vaccine used. There are very little data on the efficacy and immunogenicity of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients with malignant disease in the active phase of treatment. This multicenter observational study aims to assess the efficacy and the immunogenicity of anti-Sars-CoV-2 vaccines in the cohort of patients treated for malignant pathology (solid or hematological tumors) at Saint Louis Hospital and in thoracic oncology patients at Bichat Hospital.

NCT ID: NCT04749212 Recruiting - Thoracic Cancer Clinical Trials

Perioperative Troponin I and NT Pro-BNP in Lung Resection

Start date: May 19, 2021
Phase:
Study type: Observational

After lung resection, troponin elevation may be regulated by mechanisms other than myocardial ischemia. Perioperative natriuretic peptides measurement may help identify changes in ventricular function during thoracic surgery. Integrating both cardiac biomarkers may improve the predictive value for cardiovascular complications after lung resection.

NCT ID: NCT04686500 Active, not recruiting - Thoracic Cancer Clinical Trials

VisionRT-based Deep Inspiration Breath-hold (DIBH) Respiratory Motion Management Strategy, A Pilot Study for Thoracic and Abdominal Tumors

Start date: March 1, 2019
Phase: N/A
Study type: Interventional

A more recent competing technology for implementing the DIBH technique is real-time surface photogrammetry using the AlignRT system (Vision RT Ltd., London, UK). AlignRT system use non-ionization near infrared light to track patient surface motion. The system has one projector projecting near infrared optical pattern on patient surface. The optical pattern is imaged by optical cameras (two per pod) at ~25 Hz. The user selects a region-of-interest (ROI) on the surface and the software calculates and displays the real-time position in six degrees (3 translations and 3 rotations) in real-time. Once the patient has matched the pre-determined DIBH position (within threshold accuracy), the radiation beam is enabled to be turned on for treatment.

NCT ID: NCT04570722 Completed - Breast Cancer Clinical Trials

Ipsilateral Peripheral Intravenous Access Procedures (The iPIVAP Study)

iPIVAP
Start date: September 20, 2021
Phase: N/A
Study type: Interventional

This pilot study will examine facilitators and barriers that impact staff uptake for implementation of practice change involving ipsilateral IV insertion in patients with axillary lymphadenectomy/dissection in a single radiology center.

NCT ID: NCT04553471 Completed - Sarcoma Clinical Trials

Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers

Start date: September 22, 2020
Phase: N/A
Study type: Interventional

This is a study evaluating the safety and efficacy of Lattice SBRT for patients with large tumors (≥ 4.5 cm) planning to undergo palliative radiotherapy.

NCT ID: NCT04507594 Completed - Clinical trials for Postoperative Complications

Measurement of Diaphragmatic Dysfunction After Thoracic Surgery

Start date: August 6, 2020
Phase:
Study type: Observational

This study aims to measure diaphragmatic dysfunction with ultrasonography and nerve stimulation of the phrenicus nerve, in patients undergoing thoracic surgery for lung and esophageal cancer, and correlate measures of diaphramatic function to clinical postoperative endpoints.

NCT ID: NCT04324437 Completed - Clinical trials for Non-small Cell Lung Cancer

eRAPID: Online Symptom Reporting in Lung Cancer

Start date: July 20, 2020
Phase: N/A
Study type: Interventional

Lung cancer is a leading cause of cancer-related ill-health and death in the United Kingdom (UK), but with advances in systemic anti-cancer therapies the prognosis for people in later stages is improving. There is growing evidence that electronic systems which enable patients to monitor and report symptoms can help improve symptom control and patient care. This study aims to investigate optimal ways of introducing an electronic symptom reporting system (eRAPID) in lung cancer care at Leeds Cancer Centre. eRAPID was developed by the University of Leeds and its integration with the electronic health records at Leeds Cancer Centre enables staff to view patient symptom reports directly. eRAPID provides advice to patients about self-management of milder symptoms, for serious symptoms patients are encouraged to contact the hospital and an alert is sent to the nurse or doctor by email. The aim of the study is to assess the feasibility and usefulness of an electronic symptom reporting system (eRAPID) for lung cancer patients and healthcare professionals during the treatment of lung cancer and during one year follow up. Two groups of patients will be recruited on the basis of their access to the internet at home (rather than randomisation). It is anticipated that approximately 100 patients will enrol into one of two groups: - Group 1: Patients with online access at home will be asked to report weekly using their own devices. - Group 2: Patients without online access will be asked to report on a tablet computer before their planned clinic appointments. The eRAPID questionnaire is based on existing eRAPID items with the addition of new items specific to lung cancer. These have been developed by the clinical team and patient groups have been consulted over the suitability of the wording used. Analysis of patient reported symptoms, quality of life and clinical information will be descriptive. Disease-related symptoms and health-related quality of life will be compared across groups of patients with a diagnosis of lung cancer. Treatment-related side effects of patients will be compared across the different types of treatment received. To determine the best means of engaging patients in systematic electronic reporting, the recruitment and compliance rate will be compared between the two patient groups. The utility of patient reported information to healthcare staff will be assessed through staff interviews.